Breast Cancer Research
Whether you have early stage breast cancer or metastatic breast cancer, research can play an important role in your treatment plan, offering you access to leading-edge treatments. It can also play an important role in other peoples’ lives. By participating in a breast cancer clinical trial, you help pave the way to new prevention, detection and treatment strategies that can offer hope to people with cancer.
As an academic medical center, we are involved in some of the most groundbreaking cancer trials available today. By choosing the USC Breast Center for your breast care, you have access to clinical trials that are helping make breast cancer a disease of the past.
- Breast cancer breakthroughs
- Breast cancer clinical trials
- Finding a cure
- Improving detection, treatment, prevention
- National Cancer Institute (NCI) designation
- Understanding breast cancer causes
What our National Cancer Institute designation means
In 1973, USC Norris Comprehensive Cancer Center was designated as one of the country’s original eight comprehensive cancer centers by the National Cancer Institute (NCI), the federal government’s principle agency for cancer research and training. As an NCI-designated cancer center, we anchor the country’s cancer research efforts, making scientific discoveries that are translated into new treatments for people with cancer. The collective work of NCI researchers has led to important medical advances that have increased the number of cancer survivors in the United States and worldwide.
USC Norris cancer research breakthroughs
Our clinician-scientists have been at the forefront of cancer research for more than 40 years, making historic breakthroughs that have changed the way we understand breast cancer and how it’s treated.
A Phase 1, Multicenter, Open-label, Multiple Dose-escalation Study of ARX788, Intravenously Administered as a Single Agent in Subjects With Advanced Cancers With HER2 ExpressionLearn More ≫
A Phase II Randomized Trial of Olaparib (NSC-747856) Administered Concurrently With Radiotherapy Versus Radiotherapy Alone for Inflammatory Breast Cancer
PRIMARY OBJECTIVE: I. To compare the invasive disease-free survival (IDFS) of patients with inflammatory breast cancer receiving concurrent administration of olaparib with standard doses of radiotherapy to the chest ...Learn More ≫
A Phase IIR/III Trial of Standard of Care Therapy With or Without Stereotactic Body Radiotherapy (SBRT) and/or Surgical Ablation for Newly Oligometastatic Breast Cancer
PRIMARY OBJECTIVES: I. To determine whether ablation (through stereotactic body radiation therapy [SBRT] [stereotactic radiosurgery] and/or surgical resection of all known metastases) in oligometastatic breast cancer patients provides a ...Learn More ≫
A Phase II Study of Neratinib Alone and in Combination With Fulvestrant in Metastatic HER2 Non-amplified But HER2 Mutant Breast CancerLearn More ≫
A Randomized Phase III Clinical Trial Evaluating Post-Mastectomy Chestwall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients With Positive Axillary Nodes Before Neoadjuvant Chemotherapy Who Convert to Pathologically Negative Axillary Nodes After Neoadjuvant Chemotherapy
PRIMARY OBJECTIVES: To evaluate whether the addition of chest wall + regional nodal radiation therapy (XRT) after mastectomy or breast + regional nodal XRT after breast conserving surgery will significantly reduce the ...Learn More ≫